Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The number of cardiac angiography and percutaneous coronary interventions (PCI) has increased
steadily in recent years. This has resulted in the increasing incidence of contrast-induced
nephropathy (CIN). Major risk factors for CIN include older age, diabetes mellitus (DM),
chronic kidney disease(CKD), the concurrent use of nephrotoxic drugs, hemodynamic
instability, etc. Importantly, DM appears to act as a risk multiplier, meaning that in a
patient with CKD it amplifies the risk of CIAKI.
The aim of this multicenter prospective, randomized, controlled study is to evaluate whether
berberine treatment during and after the perioperative period would reduce the risk of CIN in
a high-risk population of patients with both DM and CKD undergoing coronary angiography or
noncoronary angiography, and the influence of such potential benefit on short-term outcome.
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University The First Affiliated Hospital with Nanjing Medical University